How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Versus Systems Inc. provides a business-to-business software platform to drive user engagement through gamification and rewards. The company offers the eXtreme Engagement Online platform, which is ...

May 22, 2026 Scientists have uncovered a strange hidden structure formed during the creation of metallocenes, a class of sandwich-like molecules used in everything from catalysis to medicine. The ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Arthur Gies Arthur Gies is an editor for Wirecutter's tech coverage. He's ...

David Dierking has 20+ years of experience in the investment services industry. He is a contributing writer for a half dozen investment websites. Amanda Jackson has expertise in personal finance, ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.